SEARCH

SEARCH BY CITATION

References

  • Abrahamsson, B., Lennernäs, H. (2003) Application of the Biopharmaceutic Classification System now and in the future. In: Van derWaterbeemd, H., Lennernäs, H., Artursson, P. (ed.) Drug bioavailability, estimation of solubility, permeability, absorption and bioavailability. Wiley-VCH, Weinheim.
  • Abrahamsson, B., Johansson, D., Torstensson, A., Wingstrand, K. (1994) Evaluation of solubilizers in the drug release testing of hydrophilic matrix extended-release tablets of felodipine. Pharm. Res. 11: 10931097.
  • Adkin, D. A., Davis, S. S., Sparrow, R. A., Huckle, P. D., Phillips, A. J., Wilding, I. R. (1995) The effects of pharmaceutical excipients on small intestinal transit. Br. J. Clin. Pharmacol. 39: 381387.
  • Agoram, B., Woltosz, W. S., Bolger, M. B. (2001) Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50 (Suppl. 1): S41S67.
  • Amidon, G. L., Lennernas, H., Shah, V. P., Crison, J. R. (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12: 413420.
  • Barr, W. H., Zola, E. M., Candler, E. L., Hwang, S. M., Tendolkar, A. V., Shamburek, R., Parker, B., Hilty, M. D. (1994) Differential absorption of amoxicillin from the human small and large intestine. Clin. Pharmacol. Ther. 56: 279285.
  • Basit, A. W., Podczeck, F., Newton, J. M., Waddington, W. A., Ell, P. J., Lacey, L. F. (2004) Related articles, links. The use of formulation technology to assess regional gastrointestinal drug absorption in humans. Eur. J. Pharm. Sci. 21: 179189.
  • Beauchamp, L. M., Orr, G. F., De Miranda, P., Burnette, T., Krenitsky, T. A. (1992) Amino acid ester prodrugs of aciclovir. Antiviral Chem. Chemother. 3: 157164.
  • Berggren, S., Lennernäs, P., Ekelund, M., Weström, B., Hoogstraate, J., Lennernäs, H. (2003) Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. J. Pharm. Pharmacol. 55: 963972.
  • Berggren, S., Hoogstraate, J., Fagerholm, U., Lennernäs, H. (2004) Characterization of jejunal permeability and efflux of ropivacaine, lidocaine and bupivacaine in the rat using two different absorption models. Eur. J. Pharm. Sci. 21: 553560.
  • Bergstrom, C. A., Norinder, U., Luthman, K., Artursson, P. (2003) Molecular descriptors influencing melting point and their role in classification of solid drugs. J. Chem. Inf. Comput. Sci. 43: 11771185.
  • Bermejo, M., Avdeef, A., Ruiz, A., Nalda, R., Ruell, J. A., Tsinman, O., Gonzalez, I., Fernandez, C., Sanchez, G., Garrigues, T. M., Merino, V. (2004) PAMPA—a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21: 429441.
  • Blume, H. H., Schug, B. S. (1999) The biopharmaceutics classification system (BCS): class III drugs — better candidates for BA/BE waiver Eur. J. Pharm. Sci. 9: 117121.
  • Bonlokke, L., Hovgaard, L., Kristensen, H. G., Knutson, L., Lennernas, H. (2001) Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans. Eur. J. Pharm. Sci. 12: 239250.
  • Blychert, E., Wingstrand, K., Edgar, B., Lidman, K. (1990) Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets. Br. J. Clin. Pharmacol. 29: 3945.
  • CDER/FDA (2000) Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Rockville, MD.
  • CPMP (2001) Note for guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98). European Agency for the Evaluation of Medicinal Products, London.
  • Chandra, P., Brouwer, K. L. (2004) The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21: 719735.
  • Charman, W. N., Porter, C. J., Mithani, S., Dressman, J. B. (1997) Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci. 86: 269282.
  • Cheng, C. L., Yu, L. X., Lee, H. L., Yang, C. Y., Lue, C. S., Chou, C. H. (2004) Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur. J. Pharm. Sci. 22: 297304.
  • Chiou, W. L., Barve, A. (1998) Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. 15: 17921795.
  • Chiou, W. L., Chung, S. M., Wu, T. C., Ma, C. (2001) A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 39: 93101.
  • Connor, A. L., Wray, H., Cottrell, J., Wilding, I. R. (2001) A scintigraphic study to investigate the potential for altered gut distribution of loperamide from a loperamide-simethicone formulation in man. Eur. J. Pharm. Sci. 13: 369374.
  • Corrigan, O. I. (1997) The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations. Adv. Exp. Med. Biol. 423: 111128.
  • Corrigan, O. I., Gubbins, R. H., O'Driscoll, C. M. (2003) Estimation of absorption parameters from the non-steady-state phase in the rat gut perfusion model. J. Pharm. Pharmacol. 55: 487493.
  • Davis, S. S., Hardy, J. G., Fara, J. W. (1986) The intestinal transit of pharmaceutical dosage forms. Gut 27: 886892.
  • De Waziers, I., Cugnenc, P. H., Yang, C. S., Leroux, J. P., Beaune, P. H. (1990) Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253: 387394.
  • Dressman, J. B., Berardi, R. R., Dermentzoglou, L. C., Russell, T. L., Schmaltz, S. P., Barnett, J. L., Jarvenpaa, K. M. (1990) Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm. Res. 7: 756761.
  • Edgar, B., Bailey, D., Bergstrand, R., Johnsson, G., Regardh, C. G. (1992) Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine—and its potential clinical relevance. Eur. J. Clin. Pharmacol. 42: 313317.
  • Egan, W. J., Lauri, G. (2002) Prediction of intestinal permeability. Adv. Drug Deliv. Rev. 31: 273289.
  • Eriksson, B. I., Arfwidsson, A. C., Frison, L., Eriksson, U. G., Bylock, A., Kalebo, P., Fager, G., Gustafsson, D. (2002) A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in orthopaedic surgery. Thromb. Haemost. 87: 231237.
  • Eriksson, U. G., Bredberg, U., Hoffmann, K.-J., Thuresson, A., Gabrielsson, M., Ericsson, H., Ahnoff, M., Gislen, K., Fager, G., Gustafsson, D. (2003) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab. Dispos. 31: 294305.
  • Ettmayer, P., Amidon, G. L., Clement, B., Testa, B. (2004) Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 47: 23932404.
  • Fagerholm, U., Johansson, M., Lennernäs, H. (1996) The correlation between rat and human small intestinal permeability to drugs with different physico-chemical properties. Pharm. Res. 13: 13351341.
  • Fagerholm, U., Lindahl, A., Lennernäs, H. (1997) Regional intestinal permeability in rats for compounds with different physico-chemical properties and transport mechanisms. J. Pharm. Pharmacol. 49: 687690.
  • Fagerholm, U., Sjöström, B., Sroka-Markovic, J., Wijk, A., Svensson, M., Lennernäs, H. (1998) The effect of a lipid drug delivery system — soybean phosphatidyl choline/medium chain monoacylglycerol matrix — on intestinal absorption of hexarelin and atenol in the rat. J. Pharm. Pharmacol. 50: 467473.
  • Fagerholm, U., Nilsson, D., Knutson, L., Lennernäs, H. (1999) Jejunal permeability in humans in vivo and rat in situ: investigation of molecular size selectivity and solvent drag. Acta Physiol. Scand. 165: 315324.
  • Fichert, T., Yazdanian, M., Proudfoot, J. R. (2003) A structure-permeability study of small drug-like molecules. Bioorg. Med. Chem. Lett. 13: 719722.
  • Fleisher, D., Li, C., Zhou, Y., Pao, L. H., Karim, A. (1999) Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin. Pharmacokinet. 36: 233254.
  • Gleiter, C. H., Morike, K. E. (2002) Clinical pharmacokinetics of candesartan. Clin. Pharmacokinet. 41: 717.
  • Goldin, B. R. (1990) Intestinal microflora: metabolism of drugs and carcinogens. Ann. Med. 22: 4348.
  • Gottfries, J., Svenheden, A., Alpsten, M., Bake, B., Larsson, A., Idstrom, J. P. (1996) Gastrointestinal transit of amoxicillin modified-release tablets and a placebo tablet including pharmacokinetic assessments of amoxicillin. Scand. J. Gastroenterol. 31: 4953.
  • Grass, G. M., Sinko, P. J. (2002) Physiologically-based pharmacokinetic simulation modelling. Adv. Drug Deliv. Rev. 54: 433451.
  • Grundy, J. S., Foster, R. T. (1996) The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin. Pharmacokinet. 30: 2851.
  • Han, H. K., De Vrueh, R. L. A., Rhie, J. K., Covitz, K.-M. Y., Smith, P. L., Lee, C.-P., Oh, D.-M., Sadee, W., Amidon, G. L. (1998) 5′-Amino acid esters of antiviral nucleosides, aciclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 15: 11541159.
  • Hu, J., Johnston, K. P., Williams, R. O. (2004) Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev. Ind. Pharm. 30: 233245.
  • Kasim, N. A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lennernäs, H., Hussain, A. S., Amidon, G. L. (2004) A provisional biopharmaceutic classification of orally administered WHO essential medicines based on molecular properties: implications for bioequivalence regulatory standards. Mol. Pharm. 1: 8596.
  • Kato, Y., Onishi, H., Machida, Y. (2003) Application of chitin and chitosan derivatives in the pharmaceutical field. Curr. Pharm. Biotechnol. 4: 303309.
  • Klausner, E. A., Lavy, E., Friedman, M., Hoffman, A. (2003) Expandable gastroretentive dosage forms. J. Control. Release 90: 143162.
  • Klein, S., Butler, J., Hempenstall, J. M., Reppas, C., Dressman, J. B. (2004) Media to simulate the postprandial stomach I. Matching the physicochemical characteristics of standard breakfasts. J. Pharm. Pharmacol. 56: 605610.
  • Kossena, G. A., Charman, W. N., Boyd, B. J., Dunstan, D. E., Porter, C. J. (2004) Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach. J. Pharm. Sci. 93: 332348.
  • Kostewicz, E. S., Brauns, U., Becker, R., Dressman, J. B. (2002) Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm. Res. 19: 345349.
  • Kostewicz, E. S., Wunderlich, M., Brauns, U., Becker, R., Bock, T., Dressman, J. B. (2004) Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J. Pharm. Pharmacol. 56: 4351.
  • Lajiness, M. S., Vieth, M., Erickson, J. (2004) Molecular properties that influence oral drug-like behavior. Curr. Opin. Drug Discov. Dev. 7: 470457.
  • Lennernäs, H. (1997) Human jejunal effective permeability and its correlation to preclinical drug absorption models. J. Pharm. Pharmacol. 49: 627638.
  • Lennernäs, H. (1998) Human intestinal permeability: an overview. J. Pharm. Sci. 87: 403410.
  • Lennernas, H. (2003) Intestinal drug absorption and bioavailability: beyond involvement of single transport function. J. Pharm. Pharmacol. 55: 429433.
  • Lennernäs, H., Nilsson, D., Aquilonius, S.-M., Ahrenstedt, Ö., Knutson, L., Paalzow, L. K. (1993) The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br. J. Clin. Pharmacol. 35: 243250.
  • Lennernäs, H., Palm, K., Fagerholm, U., Artursson, P. (1996) Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. Int. J. Pharm. 127: 1: 103107.
  • Lennernäs, H., Gjellan, K., Hällgren, R., Graffner, C. (2002a) The influence of caprate on rectal absorption of phenoxymetylpenicillin: experience from an in-vivo perfusion in humans. J. Pharm. Pharmacol. 54: 499508.
  • Lennernäs, H., Knutson, L., Knutson, T., Hussain, A., Lesko, L., Salmonson, T., Amidon, G. L. (2002b) The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. Eur. J. Pharm. Sci. 15: 271277.
  • Lindahl, A., Sandström, R., Ungell, A.-L., Abrahmsson, B., Knutson, L., Knutson, T., Lennernäs, H. (1996) Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin. Pharm. Ther. 60: 493503.
  • Lindahl A., Ungell A-L., Lennernäs H. (1997) Characterisation of fluids from the human stomach and proximal jejunum in the fasted state. Pharm. Res. 14: 497502.
  • Lindahl, A., Sjöberg, Å., Bredberg, U., Toreson, H., Ungell, A. L., Lennernäs, H. (2004) Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. Mol. Pharm. 1: 347356.
  • Lipinski, C. A., Lombardo, F., Dominy, B. W., Feeney, P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46: 326.
  • Mahato, R. I., Narang, A. S., Thoma, L., Miller, D. D. (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 20: 153214.
  • Mizuno, N., Niwa, T., Yotsumoto, Y., Sugiyama, Y. (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 55: 425461.
  • Mrestani, Y., Bretschneider, B., Hartl, A., Neubert, R. H. (2003) In-vitro and in-vivo studies of cefpirom using bile salts as absorption enhancers. J. Pharm. Pharmacol. 55: 16011606.
  • Nakamura, T., Sakaeda, T., Ohmoto, N., Tamura, T., Aoyama, N., Shirakawa, T., Kamigaki, T., Nakamura, T., Kim, K. I., Kim, S. R., Kuroda, Y., Matsuo, M., Kasuga, M., Okumura, K. (2002) Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab. Dispos. 30: 46.
  • Obata, K., Sugano, K., Machida, M., Aso, Y. (2004) Biopharmaceutics classification by high throughput solubility assay and PAMPA. Drug Dev. Ind. Pharm. 30: 181185.
  • Oberle, R. L., Chen, T. S., Lloyd, C., Barnett, J. L., Owyang, C., Meyer, J., Amidon, G. L. (1990) The influence of the inter-digestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 99: 12751282.
  • Oh, D. M., Sinko, P. J., Amidon, G. L. (1993) Characterization of the oral absorption of some beta-lactams: effect of the alpha-amino side chain group. J. Pharm. Sci. 82: 897900.
  • Patravale, V. B., Abhijit, A. D., Kulkarni, R. M. (2004) Nano-suspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 56: 827840.
  • Petri, N., Lennernäs, H. (2003) In vivo permeability studies in the GI tract. In: Van derWaterbeemd, H., Lennernäs, H., Artursson, P. (ed.) Drug bioavailability, estimation of solubility, permeability, absorption and bioavailability. Wiley-VCH, Berlin, Germany, pp 345386.
  • Petri, N., Tannergren, C., Rungstad, D., Lennernäs, H. (2004) Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm. Res. In press.
  • Polli, J. E., Yu, L. X., Cook, J. A., Amidon, G. L., Borchardt, R. T., Burnside, B. A., Burton, P. S., Chen, M. L., Conner, D. P., Faustino, P. J., Hawi, A. A., Hussain, A. S., Joshi, H. N., Kwei, G., Lee, V. H., Lesko, L. J., Lipper, R. A., Loper, A. E., Nerurkar, S. G., Polli, J. W., Sanvordeker, D. R., Taneja, R., Uppoor, R. S., Vattikonda, C. S., Wilding, I., Zhang, G. (2004) Summary workshop report: biopharmaceutics classification system—implementation challenges and extension opportunities. J. Pharm. Sci. 93: 13751381.
  • Porter, C. J., Kaukonen, A. M., Taillardat-Bertschinger, A., Boyd, B. J., O'Connor, J. M., Edwards, G. A., Charman, W. N. (2004) Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. J. Pharm. Sci. 93: 11101121.
  • Rekhi, G. S., Eddington, N. D., Fossler, M. J., Schwartz, P., Lesko, L. J., Augsburger, L. L. (1997) Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations. Pharm. Dev. Technol. 2: 1124.
  • Rowland, M., Tozer, T. N. (1995) Clinical pharmacokinetics: concepts and applications. 3rd edn, Williams & Wilkins, Media.
  • Rowland, M., Balant, L., Peck, C. (2004) Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29–30, 2002). AAPS PharmSci. 09; 6 (1): E6.
  • Sandström, R., Karlsson, A., Knutson, L., Lennernäs, H. (1998) Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res. 15: 856862.
  • Sarna, S. K. (1985) Cyclic motor activity; migrating motor complex. Gastroenterology 89: 894913.
  • Schipper, N. G. M., Vrum, K. M., Stenberg, P., Ocklind, G., Lennernäs, H., Artursson, P. (1999) Chitosans as absorption enhancers of poorly absorbable drugs. 3: influence of mucus on absorption. Eur. J. Pharm. Sci. 8: 335343.
  • Scholz, A., Kostewicz, E., Abrahamsson, B., Dressman, J. B. (2003) Can the USP paddle method be used to represent in-vivo hydrodynamics J. Pharm. Pharmacol. 55: 443451.
  • Shiraga, T., Miyamoto, K., Tanaka, H., Yamamoto, H., Taketani, Y., Morita, K., Tamai, I., Tsuji, A., Takeda, E. (1999) Cellular and molecular mechanisms of dietary regulation on rat intestinal H+/peptide transporter PepT1. Gastroenterology 116: 354362.
  • Steffansen, B., Nielsen, C. U., Brodin, B., Eriksson, A. H., Andersen, R., Frokjaer, S. (2004) Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. Eur. J. Pharm. Sci. 21: 316.
  • Sun, H. (2004) A universal molecular descriptor system for prediction of logP, logS, logBB, and absorption. J. Chem. Inf. Comput. Sci. 44: 748757.
  • Sun, D., Lennernäs, H., Welage, L. S., Barnett, J. L., Landowski, C. P., Foster, D., Fleisher, D., Lee, K.-D., Amidon, G. L. (2002) Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19: 14001416.
  • Sunesen, V. H. (2003) Biorelevant dissolution media to simulate in vivo dissolution of poorly soluble drugs. Ph.D. thesis, Danish Pharmaceutical University.
  • Swaan, P. W., Tukker, J. J. (1997) Molecular determinants of recognition for the intestinal peptide carrier. J. Pharm. Sci. 86: 596602.
  • Tannergren, C., Petri, N., Knutson, L., Hedeland, M., Bondesson, U., Lennernäs, H. (2003a) Multiple transport mechanisms involved in the intestinal absorption and first pass extraction of fexofenadine. Clin. Pharmacol. Ther. 74: 423436.
  • Tannergren, C., Knutson, T., Knutson, L., Lennernäs, H. (2003b) The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br. J. Clin. Pharmacol. 55: 182190.
  • Thamotharan, M., Bawani, S. Z., Zhou, X., Adibi, S. A. (1999) Hormonal regulation of oligopeptide transporter pept-1 in a human intestinal cell line. Am. J. Physiol. 276: C821C826.
  • Thomsen, A. E., Friedrichsen, G. M., Sorensen, A. H., Andersen, R., Nielsen, C. U., Brodin, B., Begtrup, M., Frokjaer, S., Steffansen, B. (2003) Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism. J. Control. Release 86: 279292 and 88: 343 (erratum).
  • Uchiyama, T., Sugiyama, T., Quan, Y. S., Kotani, A., Okada, N., Fujita, T., Muranishi, S., Yamamoto, A. (1999) Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: their intestinal mucosal toxicity and absorption-enhancing mechanism of n-lauryl-beta-D-maltopyranoside. J. Pharm. Pharmacol. 51: 12411250.
  • Ungell, A.-L., Nylander, S., Bergstrand, S., Sjöberg, Å., Lennernäs, H. (1998) Membrane transport of drugs in different regions of the intestinal tract of the rat. J. Pharm. Sci. 87: 360366.
  • Van de Waterbeemd, H. (1998) The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. Eur. J. Pharm. Sci. 7: 13.
  • Van de Waterbeemd, H., Gifford, E. (2003) ADMET in silico modelling: towards prediction paradise Nat. Rev. Drug Discov. 2: 192204.
  • Van de Waterbeemd, H., Smith, D. A., Beaumont, K., Walker, D. K. (2001) Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44: 13131333.
  • Van Montfoort, J. E., Hagenbuch, B., Groothuis, G. M., Koepsell, H., Meier, P. J., Meijer, D. F. (2003) Drug uptake systems in liver and kidney. Curr. Drug Metab. 4: 185211.
  • Vogelpoel, H., Welink, J., Amidon, G. L., Junginger, H. E., Midha, K. K., Moller, H., Olling, M., Shah, V. P., Barends, D. M. (2004) Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J. Pharm. Sci. 93: 19451956.
  • Volpe, D. A. (2004) Permeability classification of representative fluoroquinolones by a cell culture method. AAPS Pharm Sci. 6: 16.
  • Von Richter, O., Greiner, B., Fromm, M. F., Fraser, R., Omari, T., Barclay, M. L., Dent, J., Somogyi, A. A., Eichelbaum, M. (2001) Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin. Pharmacol. Ther. 70: 217227.
  • Winiwarter, S., Bonham, N., Hallberg, A., Lennernäs, H., Karlén, A. (1999) Correlation of human jejunal permeability (in vivo) with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41: 49394949.
  • Winiwarter, S., Ax, F., Lennernäs, H., Hallberg, A., Pettersson, C., Karlén, A. (2003) Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. J. Mol. Graph. Model. 21: 283287.
  • Wu, C. Y., Benet, L. Z., Hebert, M. F., Gupta, S. K., Rowland, M., Gomez, D. Y., Wacher, V. J. (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 58: 492497.
  • Yazdanian, M., Briggs, K., Jankovsky, C., Hawi, A. (2004) The “high solubility” definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm. Res. 21: 293299.
  • Yu, L. X., Ellison, C. D., Conner, D. P., Lesko, L. J., Hussain, A. S. (2001) Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs. AAPS PharmSci. 3: E24.
  • Yu, L. X., Amidon, G. L., Polli, J. E., Zhao, H., Mehta, M. U., Conner, D. P., Shah, V. P., Lesko, L. J., Chen, M. L., Lee, V. H., Hussain, A. S. (2002) Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19: 921925.
  • Yu, L. X., Straughn, A. B., Faustino, P. J., Yang, Y., Parekh, A., Ciavarella, A. B., Asafu-Adjaye, E., Mehta, M. U., Conner, D. P., Lesko, L. J., Hussain, A. S. (2004) The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs. Mol. Pharm. 5: 357362.
  • Ziessman, H. A., Fahey, F. H., Collen, M. J. (1992) Biphasic solid and liquid gastric emptying in normal controls and diabetics using continuous acquisition in LAO view. Dig. Dis. Sci. 37: 744750.